CTZ

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of CTZ

What is CTZ? An Overview

The following section provides a structured, fact-based overview of CTZ (Cetirizine Hydrochloride), focusing strictly on its identity, classification, and general function.

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, capsule, oral solution
Pharmacological class Second-Generation Antihistamine
General purpose Reduction of overall allergic response
Origin Synthetic, Piperazine derivative

What is CTZ and What is its Core Composition?

CTZ is a medicinal preparation whose sole active ingredient is Cetirizine Hydrochloride, a synthetic compound designed to target allergic responses. This medication is classified as a single-ingredient product, commonly supplied for oral administration in various dosage forms, including the familiar tablet, capsule, and liquid oral solution. The use of Cetirizine in these forms is recognized for its reliable absorption profile. The chemical foundation of Cetirizine is derived from the piperazine family, making it a synthetic agent. The oral solution form is often preferred for patient groups, such as children, who may have difficulty swallowing tablets.

What Type of Antihistamine is Cetirizine?

Cetirizine Hydrochloride is categorized scientifically as a second-generation antihistamine and a highly selective H1 receptor antagonist. This classification distinguishes it from older first-generation agents by its focused action: it primarily blocks histamine receptors located in the body's peripheral tissues. Cetirizine has a high affinity for peripheral H1 receptors, which characterizes its role as a selective agent. This means the drug targets the areas where physical allergy symptoms occur most directly, without the significant sedative effects characteristic of first-generation compounds.

What is the General Purpose of CTZ?

The general purpose of CTZ is to reduce the body's overall allergic response by intercepting the signal that causes allergic symptoms. It achieves this by executing a targeted histamine blockade, preventing the naturally released chemical, histamine, from binding to its receptors in the body's tissues. This selective mechanism provides symptomatic relief from the physical manifestations commonly associated with allergic reactions, such as irritation and swelling. This function is its primary therapeutic action.

What side effects are possible with CTZ?

Possible Side Effects and Safety Information

The safety profile of Cetirizine Hydrochloride (CTZ) is formally defined by regulatory agencies based on clinical trial data and post-market experience, categorizing adverse reactions by frequency and organ system. The classifications reflect the probability of occurrence, ranging from common to very rare.

Common and Expected Adverse Reactions

Adverse reactions classified as common (occurring in 1 in 100 to 1 in 10 patients) typically involve central nervous system and gastrointestinal systems. These officially documented effects include somnolence (drowsiness), headache, fatigue, dizziness, dry mouth, and nausea. Regulatory documents note that somnolence is more likely to occur at the start of treatment.

System-Organ Class and Rare Events

Reactions classified as uncommon (1 in 1,000 to 1 in 100) include diarrhea, paresthesia (tingling sensation), and rash. Rare and very rare reactions are documented across several system-organ classes, including the immune system (e.g., anaphylactic shock), cardiac system (tachycardia), and nervous system (seizures, syncope). Abnormal liver function (elevated hepatic transaminases) and angioedema (severe swelling) are also listed in these lower frequency tiers.

Safety Considerations and Restrictions

Official labeling includes safety constraints for specific patient populations. Due to the medicine's primary route of excretion, it is generally restricted or not recommended for individuals with severe renal impairment and severe hepatic impairment. Caution is documented regarding activities requiring concentration, such as driving or operating machinery, due to the potential for dizziness and somnolence. Reports of intense pruritus or urticaria have also been documented upon discontinuation of the medicine.

Overdose and Emergency Response

The official regulatory profile for Cetirizine Hydrochloride overdose focuses on central nervous system (CNS) effects and the necessity for immediate supportive care. Documented overdose presentations commonly involve a sequence of manifestations.

In some cases, particularly in pediatric patients, initial restlessness and excitement may occur, followed by a phase of pronounced CNS depression, including deep somnolence or coma. Other clinical signs include systemic effects such as tachycardia (fast heart rate) and anticholinergic-like symptoms such as fixed and dilated pupils, dry mouth, and urinary retention. Overdose in children and older adults may cause more severe symptoms.

Life-threatening outcomes officially associated with severe exposure include convulsions (seizures) and potential cardiorespiratory collapse. Due to the regulatory confirmation that no specific antidote is known for Cetirizine, management is officially described as symptomatic and supportive treatment. Supportive measures may involve considering gastric lavage shortly after ingestion, with the note that the drug is not effectively removed by dialysis. Cardiac monitoring and hospital observation may be required for large-dose ingestions or when severe symptoms develop.

If an overdose is suspected, or if any severe symptoms such as loss of consciousness, a seizure, or trouble breathing are present, regulatory guidance mandates that individuals call a Poison Control Center right away and seek emergency medical attention immediately.

Therapeutic Uses of CTZ

CTZ may be part of symptomatic management, supporting relief in situations involving certain distressing symptoms related to heightened physiological activity associated with allergy symptoms. It is applied across domains where additional symptomatic support is needed to help manage acute or episodic changes, particularly those that interfere with daily functioning. CTZ is commonly used to help with allergic rhinitis and chronic urticaria, which is consistent with its role in managing both respiratory and skin-related allergic conditions.

The medication is commonly used across conditions characterized by periods of heightened symptoms such as seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria. It helps address symptom clusters that may become intense or disruptive, focusing on manifestations like frequent sneezing, watery rhinorrhea, persistent nasal itching, and disruptive skin pruritus with wheals. This assistance supports the patient during difficult episodes by easing distress and contributes to maintaining functional stability when symptoms are more noticeable, such as during high-pollen seasons or year-round indoor allergen exposure.


Quick Fact: Core Symptom Focus

CTZ is relevant for easing symptoms related to inflammatory or irritative states, applied across domains where additional symptomatic support is needed for managing Pruritus (Itching) and Rhinorrhea (Runny Nose).

Eligibility and Restrictions for Use

The eligibility for using CTZ (Cetirizine Hydrochloride) is strictly defined by regulatory authorities based on age, hypersensitivity, and underlying health conditions.

Absolute Contraindications (Who Must Not Use)

CTZ is contraindicated in patients with a known hypersensitivity to the active substance, cetirizine, or to any related piperazine derivatives, including hydroxyzine. Absolute non-eligibility also applies to patients diagnosed with End-Stage Renal Disease (Creatinine Clearance < 10 mL/min) and individuals with rare hereditary disorders such as galactose intolerance (for tablet formulations).


Eligibility by Age and Organ Function

Use is established for adults and adolescents ( 12 years), as well as children (down to 6 years, or 6 months for specific forms and indications). However, use is not recommended for young children with pre-existing impaired renal or hepatic function. Patients with moderate to severe renal impairment have a conditional use status and are eligible only under conditions that require regulatory-defined adjustments. Isolated hepatic impairment does not typically require specific restrictions.


Specific Restrictions and Cautionary Status

Use is a restricted status for pregnant and breastfeeding individuals; regulatory documents advise avoiding use unless necessary, due to the substance being reported in breast milk. Caution is explicitly advised for patients with a risk of convulsions and those with conditions that predispose them to urinary retention (e.g., prostatic enlargement).

What should I know about interactions with other medicines?

Interactions with other medicines and products are officially documented patterns of change in drug disposition or additive effect. The co-administration of Theophylline (400 mg daily) is documented to cause a small, but measurable, 16% decrease in Cetirizine clearance, which may lead to increased systemic exposure. As a recognized P-glycoprotein (P-gp) substrate, combining Cetirizine with P-gp inhibitors can officially lead to increased systemic levels and effect of the medicine.

A primary pharmacodynamic restriction involves Alcohol and Central Nervous System (CNS) Depressants. Concurrent use with these substances should be avoided due to the risk of additional reductions in alertness and further impairment of CNS performance. Administration with food does not reduce the extent of absorption, though the rate of absorption is officially delayed.

Interaction-Related Constraints

The official profile includes a procedural constraint: the drug's activity inhibits the response to allergy skin tests, necessitating a mandatory wash-out period prior to the test. Furthermore, patients with hepatic or renal impairment exhibit a significant decrease in drug clearance, which is a population-specific note indicating a heightened exposure risk.

Mechanism of Action

The mechanism of CTZ involves the modulation of two distinct ligand-gated ion channels within the central nervous system. Primarily, Cyclothiazide (CTZ) functions as a positive allosteric modulator (PAM) of AMPA receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors). CTZ binding to the receptor complex inhibits the rapid desensitization of the channel following agonist activation. This inhibition prolongs the duration of the open channel state, consequently increasing the total flux of positive ions across the neuronal membrane.

In parallel, CTZ acts as a non-competitive antagonist of GABA A receptors (gamma-aminobutyric acid type A receptors). By binding to a site distinct from the GABA binding pocket, CTZ reduces the efficacy of the inhibitory neurotransmitter. The combined effect of potentiating excitatory glutamatergic signaling and diminishing inhibitory GABAergic signaling results in a net increase in neuronal excitability and the subsequent potentiation of synaptic transmission within targeted brain regions.

Dosage and Administration Information

The use of Cetirizine (CTZ) is based on established protocols regarding administration route, dosage, frequency, and population-specific adjustments. The medication is primarily intended for oral administration via tablets, solutions, or syrups. An Intravenous (IV) injection is also a route utilized for acute clinical scenarios in supervised settings.

Standard Administration and Dosing

For adults and adolescents 12 years and older, the typical standard regimen is 10 mg administered once daily. An alternative starting dose of 5 mg once daily may be used for managing less severe symptoms, with the maximum daily dose limited to 10 mg. The medication may be taken with or without food. Oral tablets must be swallowed whole with liquid; the IV injection is administered as an intravenous push over a period of 1 to 2 minutes. If a dose is missed, it should be skipped if it is almost time for the next scheduled dose.

Population-Specific Adjustments

Specific patient groups require dose adjustments. For children 6 to 12 years, the dose may be divided and administered as 5 mg twice daily or 10 mg once daily. The tablet formulation is considered unsuitable for children under 6 years as it does not allow the necessary low-dose adjustment, which requires the use of liquid forms. Dosing adjustments are also essential for patients with impaired kidney function: the dose is reduced (for example, 5 mg once daily or 5 mg every two days, depending on severity) because the drug is primarily eliminated via the renal route.

Recent Clinical Evidence

The research structure for Cetirizine Hydrochloride (CTZ) focuses primarily on clinical studies and outcomes evaluated by regulators. This descriptive overview details the types of trials conducted without offering interpretation of results.


Evidence for Allergic Rhinitis (Seasonal and Perennial)

The evidence base stems from Randomized, Double-Blind, Placebo-Controlled Trials (RCTs) conducted during periods of increased symptom activity. Research explored short-term symptom changes, with observation periods often ranging from one to six weeks.

Studies measured outcomes linked to physical discomfort, such as sneezing and nasal itching, using scales like the Total Symptom Severity Complex (TSSC). They also monitored outcomes reflecting daily functioning using questionnaires like the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Research explored patterns observed in these studies by comparing measurements between the study compound and a placebo.

Evidence for Chronic Urticaria (Hives/Pruritus)

CTZ was studied for its role in research contexts involving the symptoms of chronic urticaria, which is characterized by fluctuating manifestations of hives and itching. Research involved both short-term and intermediate-term controlled trials. The primary focus was on the outcome of complete suppression of the condition’s physical manifestations. Studies monitored outcomes using tools like the Urticaria Activity Score (UAS), reporting how symptoms evolved during defined time intervals.

Research Gaps and Uncertainties

The majority of the structural evidence available for review reflects observation periods that are often limited to the short-term (under six weeks) and intermediate-term (up to 12 weeks) follow-up durations. Research examining sustained changes over periods extending past three months is generally not fully established.

Furthermore, comparative evidence is lacking against certain modern treatment options, and the pivotal trials supporting regulatory findings sometimes show modest sample sizes relative to current standards.

Key Studies & References

  1. Cetirizine: An overview of pharmacology and clinical applications (NIH StatPearls)

Frequently Asked Questions (FAQ)

Common questions about CTZ (FAQ)

Q: How quickly can someone expect CTZ to start working?

According to the official product information, the effects of CTZ generally begin within 30 minutes after taking an oral dose. In some clinical studies, relief has been examined as quickly as 20 minutes after administration.


Q: What is the difference between CTZ and other medicines used for the same condition?

Official information indicates that CTZ is classified as a second-generation H1-antihistamine. This categorization is associated with fewer central nervous system effects compared to older, first-generation agents due to its high selectivity for peripheral receptors.


Q: Are there common signs that CTZ is taking effect?

The general purpose of the medicine, as described in regulatory documents, is the reduction of the overall allergic response. Therefore, the signs that it is taking effect are typically related to the relief of the specific symptoms it is treating, such as reduced itching, hives, or nasal discomfort.


Q: How long does the effect of one dose of CTZ usually last?

Studies and official information indicate that the effects of a standard dose of CTZ generally persist for about 24 hours. This duration supports its official designation as a once-daily medicine.


Q: Does CTZ interact with common pain relievers like ibuprofen?

Regulatory documents and official drug interaction databases indicate that CTZ shows no significant drug-drug interaction when used alongside common nonsteroidal anti-inflammatory pain relievers like ibuprofen.


Q: Can CTZ be taken with multivitamins or general supplements?

Official guidance notes that health professionals should be informed of all concomitant medications and supplements, including vitamins and herbal products, to assess potential interactions.


Q: Is it okay to have coffee or caffeine while using CTZ?

The regulatory label advises that co-administration with alcohol or other Central Nervous System (CNS) depressants should be avoided due to the potential for increased drowsiness. Caffeine is a CNS stimulant, but it is not listed as a specific contraindication in official interaction warnings.


Q: Can CTZ affect weight, causing either gain or loss?

While not a common acute effect, some authoritative sources have noted that the use of H1-antihistamines, including CTZ, has been associated with weight gain in some observational studies. This association is noted in observational studies, but the specific reason is not defined in core regulatory texts.


Q: What are the considerations for CTZ use for older adults (seniors)?

Regulatory documents acknowledge that older adults may be more sensitive to adverse effects. Regulatory documents indicate that dose adjustments are often necessary for older individuals, especially those with decreased kidney function.


Q: Do people who take CTZ long-term need specific monitoring?

The risks associated with long-term use are typically reviewed by a healthcare provider. This is especially important considering the documentation of severe itching (pruritus) that may occur after stopping the medicine following daily use for months or years.


Q: Does CTZ require a prescription, or is it available over the counter?

In the United States and many other countries, CTZ is available over-the-counter (OTC) without a prescription. However, certain high-strength or combination products that include a decongestant may still require a prescription.


Q: Is CTZ considered habit-forming or addictive?

Official regulatory reviews have specifically looked into the potential for abuse and dependence. These reviews have reported no known cases of drug abuse or dependence with CTZ.


Q: Does CTZ have a Black Box Warning from the FDA?

Official FDA drug safety communications confirm that CTZ does not currently have a Boxed Warning (often called a Black Box Warning). This type of warning is the agency's most serious safety alert for drug products.


Q: What is the purpose of the inert ingredients listed in CTZ products?

The official labeling for CTZ lists both active and inactive (inert) ingredients. The inactive ingredients do not contribute to the therapeutic effect but are necessary to form the tablet, control how the drug dissolves, or add flavor to liquid forms.


Q: Does CTZ show up on standard drug screening tests?

Unlike some older antihistamines, CTZ is not typically reported to cause false-positive results on standard drug screening tests, such as those that look for amphetamines or methamphetamines.


Q: Does CTZ interact with common herbal supplements like St. John's Wort?

Official interaction studies note a risk that certain enzyme-inducing supplements, such as St. John’s Wort, may potentially reduce the level of CTZ in the body. Regulatory documents recommend informing a healthcare provider of all herbal products.


Q: What kind of information is contained in the Patient Information Leaflet for CTZ?

Patient Information Leaflets (or MedGuides) generally summarize the key information needed for safe use. This includes the drug’s purpose, administration steps, common side effects, important warnings, proper storage, and necessary drug interactions.


Q: What should a patient do if they accidentally take more CTZ than prescribed?

In line with guidance for all medications, official labeling states that in case of overdose, contacting a certified Poison Control Center or seeking emergency medical help is recommended.


Q: What is the reason CTZ is only available by prescription?

CTZ is generally available over-the-counter (OTC) in the US and many other regions. Reclassification to OTC status was supported by its established safety profile and wide margin between therapeutic and toxic doses.


Q: Have there been any recent changes in the official safety warnings for CTZ?

The prescribing information has been updated to include information regarding pruritus (severe itching) that has been documented following the discontinuation of the medicine after long-term daily use.


Q: Does CTZ have a different effect if taken in the morning versus the evening?

Official studies indicate that CTZ provides equivalent 24-hour efficacy whether it is taken in the morning or at bedtime. However, taking it at bedtime is sometimes preferred by patients due to the possibility of experiencing mild drowsiness.


Q: Why are certain interactions with CTZ classified as 'major'?

Regulatory bodies classify interactions as 'major' when the combination of drugs could potentially lead to a life-threatening or serious adverse event. This classification signals that the two drugs should typically be avoided entirely.


Q: Does CTZ cause long-term side effects that people should know about?

While the medicine has a long-established safety profile, a safety update notes the documentation of pruritus (severe itching) that has been observed following the discontinuation of the medicine after long-term daily use. Studies examining sustained changes beyond three months are limited.


Q: What kind of conditions might reduce the effectiveness of CTZ?

Official labeling notes that taking the medication with food can delay the rate of absorption but does not reduce the overall amount absorbed. Other conditions that affect drug absorption in the digestive tract may also potentially impact how quickly and effectively the medicine works.


Q: Are there any specific laboratory tests that need to be done before starting CTZ?

The product label does not mandate specific blood tests for all users, but patients should disclose a history of kidney or liver disease as dose adjustments may be required. The drug must also be stopped for a period of time before a scheduled allergy skin test.


Q: Can taking CTZ affect sleep patterns?

Drowsiness (somnolence) and excessive tiredness are common side effects listed in the official labeling. These effects may impact a person’s overall sleep-wake cycle and patterns.


Q: What does 'contraindicated' mean in the context of CTZ use?

The term 'contraindicated' means the medication must not be used by a patient. This restriction applies when the risks, such as a known hypersensitivity or a diagnosis of end-stage kidney disease, significantly outweigh any potential benefit.


Q: Are there specific official guidelines about CTZ use for patients with heart conditions?

The official safety labeling notes that individuals with a history of heart disease or high blood pressure may require consultation with a health professional prior to use.

How should CTZ be stored and disposed of?

Official Storage and Disposal Instructions for Cetirizine (CTZ)


Storage Conditions

Cetirizine must be stored at Controlled Room Temperature, defined as 20^circC to 25^circC (68^circF to 77^circF), as specified in regulatory labeling. The product must be kept in its original container and maintained in a dry place, protected from high humidity and excessive heat. It is mandatory to store the medication out of the sight and reach of children to prevent accidental ingestion.

Storage Requirement Specification
Temperature Range 20^circC to 25^circC
Environmental Protection Protect from high humidity and excessive heat
Container Rule Keep in original, tightly closed container

Disposal Guidelines

Disposal must follow official regulatory guidance. The preferred method for discarding unused or expired cetirizine is using a drug take-back program. If this option is unavailable, the medication should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. Cetirizine is not on the list of medications recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of CTZ found in:

A-Z Index: